Ikarian Capital’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Ikarian Capital's MNPR Position: Q3 2026 in Review
Ikarian Capital increased its Monopar Therapeutics (MNPR) stake by 81% in Q3 2026, buying an estimated $4.17M and bringing the position to 86,761 shares worth $6.91M. The position accounts for 0.7% of the portfolio, ranked #37.
Ikarian Capital first reported a position in MNPR in Q4 2024 and has held it in 4 quarters since. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Ikarian Capital held 86,761 shares of Monopar Therapeutics worth $6.91M as of Q3 2026.
- Ikarian Capital bought 38,900 Monopar Therapeutics shares in Q3 2026, an estimated $4.17M.
- Monopar Therapeutics made up 0.7% of Ikarian Capital's portfolio in Q3 2026, its #37 holding.
- Ikarian Capital first reported a position in Monopar Therapeutics in Q4 2024 and has held it in 4 quarters since.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.